PCV34 THE COST-EFFECTIVENESS OF ALISKIREN AS ADD ON TO LOSARTAN AND OPTIMAL ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION AND NEPHROPATHY IN THE UNITED KINGDOM SETTING
May 1, 2008, 00:00
10.1016/S1098-3015(10)70622-7
https://www.valueinhealthjournal.com/article/S1098-3015(10)70622-7/fulltext
Title :
PCV34 THE COST-EFFECTIVENESS OF ALISKIREN AS ADD ON TO LOSARTAN AND OPTIMAL ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION AND NEPHROPATHY IN THE UNITED KINGDOM SETTING
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)70622-7&doi=10.1016/S1098-3015(10)70622-7
First page :
Section Title :
Open access? :
No
Section Order :
353